- 20
- 1 859
Odylia Therapeutics
เข้าร่วมเมื่อ 2 มี.ค. 2021
Odylia is a unique nonprofit biotech bringing life-changing treatments to people with rare genetic disorders, regardless of prevalence or commercial interest. We help groups navigate the complexity of bringing treatments from the lab to patients.
Brydge Solutions Case Study
A case study on Odylia's collaboration with the Usher 2020 Foundation. Accelerating development of a gene therapy for vision loss caused by mutations in the USH1C gene.
มุมมอง: 12
วีดีโอ
Episode 5. What is a drug repurposing screen?
มุมมอง 39หลายเดือนก่อน
Odylia believes in empowering the rare disease community through access to resources that will assist in their drug development journey. This series addresses common questions and roadblocks that face groups as they work to develop therapies. In this video we discuss drug repurposing screens and detail what they entail and how they can lead to quicker approvals for drugs for rare diseases. Plea...
The Odylia Collective
มุมมอง 14หลายเดือนก่อน
The Odylia Collective Odylia is building a centralized marketplace to ensure critical resources are findable and accessible for patient groups and other members of the rare disease research community. Ultimately, centralizing these resources will decrease wasted time and money, and increase the speed at which drugs are developed for rare diseases. Driven by the complexity in connecting the disp...
RPGRIP1 Gene Therapy Program Update: June 2024
มุมมอง 131หลายเดือนก่อน
Odylia Therapeutics provides an update on the RPGRIP1 Gene Therapy program (OT-004) and hosts a Q&A session. June 2024. Odylia Therapeutics, a nonprofit biotechnology company, received a Translation Research Award for $1.5 million from the Foundation Fighting Blindness to accelerate the development of a novel gene therapy (OT-004) to treat vision loss caused by mutations in the RPGRIP1 gene.
Episode 4: What should I consider when forming a scientific advisory board? (Part 2)
มุมมอง 577 หลายเดือนก่อน
Odylia believes in empowering the rare disease community through access to resources that will assist in their drug development journey. This series addresses common questions and roadblocks that face groups as they work to develop therapies. In this video we discuss Scientific Advisory Boards (SABs) for Patient Advocacy Organizations with two members of the Odylia team who have diverse backgro...
Episode 3: What should I consider when forming a scientific advisory board? (Part 1)
มุมมอง 497 หลายเดือนก่อน
Odylia believes in empowering the rare disease community through access to resources that will assist in their drug development journey. This series addresses common questions and roadblocks that face groups as they work to develop therapies. In this video we discuss Scientific Advisory Boards (SABs) for Patient Advocacy Organizations with two members of the Odylia team who have diverse backgro...
RPGRIP1 Gene Therapy Program- Community Q&A (November 8, 2023)
มุมมอง 748 หลายเดือนก่อน
Community questions and program updates. Links mentioned during the Q&A: -Reach out with any questions: info@odylia.org -Odylia launches our new online store: www.bonfire.com/store/odylia-therapeutics/
Episode 2: What are research tools and when do I invest in them?
มุมมอง 718 หลายเดือนก่อน
Odylia believes in empowering the rare disease community through access to resources that will assist in their drug development journey. This series addresses common questions and roadblocks that face groups as they work to develop therapies. In this video we discuss research tools - what they are and how they are useful for understanding disease biology and identifying potential therapeutics. ...
Episode 1: Where can I find free resources on drug development for rare disease?
มุมมอง 8010 หลายเดือนก่อน
Odylia believes in empowering the rare disease community through access to resources that will assist in their drug development journey. This video series addresses common questions and roadblocks that face groups as they work to develop therapies. Please subscribe to get the latest releases and feel free to comment or send us an email (info@odylia.org) if you have ideas for future videos. Free...
Odylia Brydge Solutions- SATB2 Gene Foundation Spring Update
มุมมอง 39ปีที่แล้ว
SATB2 Gene Foundation partnered with Odylia Therapeutics' Brydge Solutions to establish an independent assessment of the SATB2 research landscape. Odylia’s report, combined with a survey of SATB2 families and their needs, led to the foundation of the SATB2 Gene Foundation research strategic plan. This video provides a short overview of SATB2, Odylia's Brydge Soltuions, and outcomes from the rep...
Meet Dylan & Brayden
มุมมอง 10ปีที่แล้ว
Brayden regularly makes videos for his TH-cam channel (@atxcards ) On this one, he highlighted his sister's fundraiser for the RPGRIP1 Gene Therapy Program. We appreciate his support and his creativity! Check it out here: www.every.org/odyliatherapeutics/f/help-save-dylans-vis If you would like to setup your own fundraising page visit www.every.org/odyliatherapeutics/fundraiser About Brayden: I...
RPGRIP1 Gene Therapy Program- May 2023 Community Q&A
มุมมอง 236ปีที่แล้ว
Odylia Therapeutics hosts a Q&A session for the RPGRIP1 Gene Therapy program (OT-004).
BioNeex Interview with Co-Founder & CEO of Odylia Therapeutics, Scott Dorfman (Short)
มุมมอง 42ปีที่แล้ว
BioNeex Founder, Smbat Rafayelyan sat down with Odylia Therapeutics CEO and co-Founder, Scott Dorfman to discuss Odylia's nonprofit approach to drug development and our lead gene therapy program to treat vision loss caused by mutations in RPGRIP1. Full interview can be found here: bioneex.com/interviews/interview-with-co-founder-ceo-of-odylia-therapeutics-scott-dorfman/ About Odylia Therapeutic...
Odylia Therapeutics: RPGRIP1 Gene Therapy to Treat RPGRIP1 related vision loss- February 2022 update
มุมมอง 2642 ปีที่แล้ว
Aired February 3, 2022: Odylia Therapeutics' President and CSO, Ashley Winslow, and Director of Development, Heather Greene, provide an update on Odylia's RPGRIP1 Gene Therapy program to treat vision loss in patients diagnosed with Leber Congenital Amaurosis 6 (LCA6), Cone rod dystrophy 13 (CORD13), and juvenile Retinitis Pigmentosa caused by mutations in RPGRIP1.To support the RPGRIP1 program ...
Odylia Therapeutics: RPGRIP1 Gene Therapy to Treat RPGRIP1 related vision loss (September, 2021)
มุมมอง 2292 ปีที่แล้ว
Odylia Therapeutics: RPGRIP1 Gene Therapy to Treat RPGRIP1 related vision loss (September, 2021)
Odylia Therapeutics & Foundation Fighting Blindness Webinar Series (#1)
มุมมอง 783 ปีที่แล้ว
Odylia Therapeutics & Foundation Fighting Blindness Webinar Series (#1)
Odylia Therapeutics & Foundation Fighting Blindness Webinar Series (#4)
มุมมอง 323 ปีที่แล้ว
Odylia Therapeutics & Foundation Fighting Blindness Webinar Series (#4)
Odylia Therapeutics & Foundation Fighting Blindness Webinar Series (#3)
มุมมอง 483 ปีที่แล้ว
Odylia Therapeutics & Foundation Fighting Blindness Webinar Series (#3)
Odylia Therapeutics & Foundation Fighting Blindness Webinar Series (#2)
มุมมอง 1103 ปีที่แล้ว
Odylia Therapeutics & Foundation Fighting Blindness Webinar Series (#2)
Great video!!! Are you planning one?
I have done two genetic testing and they says the same thing
Hi, feel free to reach out if you would like more information on RPGRIP1 or Odylia's RPGRIP1 Gene Therapy Program. Email us at info@odylia.org
This is the condition I suffer from.
If you would like to stay up-to-date on the progress of Odylia's RPGRIP1 gene therapy you can sign-up for our Newsletter at odyliatherapeutics.salsalabs.org/NewsletterSignupForm/index.html And visit our website to learn more at odylia.org/
Amazing 👏 My child has congenital cone rod dystrophy. He is now 6 years old. I have been following Dr. Eric Pierce’s research. Very hopeful for the future for my child 🙏
Thanks for connecting and stay in touch!